Roche’s Perjeta for Breast Cancer Wins Approval
By Anna Edney -
2012-06-11T16:42:28Z
(Corrects drug spelling in headline, second paragraph of story published June 8.)
Roche Holding AG (ROG)’s personalized drug treatment for a fast-growing type of breast cancer won approval from U.S. regulators.
Perjeta, chemically known as pertuzumab, is designed to work with the Basel, Switzerland-based company’s Herceptin and chemotherapy to attack breast cancer that has spread in patients who have a certain gene mutation. The Food and Drug Administration today cleared Perjeta for consumer use, Roche’s Genentech unit said in a statement.
To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net.
To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net
More News:
Sponsored Link
Rate this Page
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.